Skip to content
Ejaculation.org

Meta-analysis · 2016

Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z (2016). Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. The Journal of Sexual Medicine. doi:10.1016/j.jsxm.2016.07.006

Key finding
Pooling 17 randomised trials (17,494 men), finasteride and dutasteride raised the risk of sexual dysfunction in men treated for an enlarged prostate (relative risk 2.56), but not significantly in men treated for hair loss (1.21).

Summary

5-alpha reductase inhibitors (5ARIs), finasteride and dutasteride, are used to treat an enlarged prostate (benign prostatic hyperplasia, BPH) and male-pattern hair loss (androgenetic alopecia). This meta-analysis searched Medline, Embase and Cochrane up to October 2015 and included 17 randomised controlled trials with 17,494 men: nine in BPH and eight in hair loss. The mean age across studies was 60.1 years.

In men with BPH, 5ARIs raised the pooled relative risk of sexual dysfunction to 2.56 (95% CI 1.48 to 4.42), of erectile dysfunction to 1.55 and of decreased libido to 1.69 compared with placebo. In men treated for hair loss, the corresponding relative risks (1.21 for sexual dysfunction, 0.66 for erectile dysfunction and 1.16 for decreased libido) were not statistically significant. No publication bias was found.

Limitations

Ejaculatory problems were not analysed as a separate outcome in the abstract. The abstract reports only a pooled mean age (60.1 years) and does not compare age or dose between the BPH and hair-loss groups; in practice hair-loss treatment uses a lower finasteride dose (1 mg vs 5 mg a day), so the two groups are not directly comparable. The authors call for better-designed trials on the mechanism.

What it means for you

In controlled trials, sexual side effects of finasteride and dutasteride were clearly more common than with placebo in men treated for the prostate, and less clear-cut in men treated for hair loss. If you notice changes, talk to your prescriber rather than stopping on your own.